Please type a plus sign (+) inside this box

Gay 1649

PTO/SB/21 (08-00)

Approval for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control

number.

TRANSMITTAL					Application Numb	er	09/771,961	DEOE	
				Filing Date		Jan 29, 2001	RECEIV	(ED	
FORM					First Named Inver	ntor	Turner	OCT 112	102
. 511				Group Art Unit		1647	TECH CENTER 16	00/2900	
(to be used for all correspondence after initial filing)					Examiner Name		F.M. Hamud		
Total Number of Pages in This Submission 19				Attorney Docket Number		LEX-0121-USA			
ENCLOSURES (check all that apply)									,]
	Fee Transmi	ttal Form	<i>/</i>	Assignme				Communication	
	Fee	Attached		Orawing(s			•	nication to Board	
×	Amendment / Reply After Final		Licensing-related Papers Petition				Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information		
·									
	Affidavits/declaration(s)			Petition to Convert to a Provisional Application			Status Letter		
	Extension of Time Request			Power of Attorney, Revocation Change of Correspondence Address			Other Enclosure identify below):	e(s) (please	
	Express Abandonment Request			Terminal Disclaimer			return postcard		
	Information Disclosure Statement		l F	Request for Refund					
	Certified Copy of Priority Document(s)		CD, Number of CD(s)						
Response to Missing Parts/ Incomplete Application			Remarks						
Response to Missing Parts under 37 CFR 1.52									
or 1.53			24231 PATENT TRADEMARK OFFICE						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT									
Firm or Lance K. Ishimoto Reg. No. 41,866 Individual name Lexicon Genetics Incorporated									
Sign	ature	MICHARD	They Velde Son Royabyo162 Roter G Seferiain						
Date October 2, 2002									
CERTIFICATE OF MAILING									
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202 on October 2, 2002 this date:									
Typed or printed name Nancy Stacey									
Signa	ture		A	4		Date	October 2, 200	2	

Burden Hour Statement: This form is estimated to ake 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Turner et al.

Group Art Unit: 1647

RECEIVED

Application No.:

09/771,961

OCT 1 1 2002

Filed:

01/29/01

Examiner: F.M. Hamud TECH CENTER 1600/2900

Polynucleotides Encoding the Same

Title: Novel Human Membrane Proteins and

Atty. Docket No.: LEX-0121-USA

AMENDMENT AND RESPONSE TO OFFICE ACTION DATED JULY 2, 2002

Commissioner for Patents Arlington, VA 22202

Sir:

Applicants acknowledge the receipt of the Office Action ("the Action") mailed on July 2, 2002, which has been carefully reviewed and studied. The Examiner is respectfully requested to enter the following amendments. Reexamination and reconsideration of the application is requested in view of the following amendments and remarks. In order to facilitate the Examiner's evaluation of the application, Applicants have attempted to address the objections and rejections in the same order in which they were originally raised.

The response is thus timely filed. Applicants believe no fees in addition to the fee for the extension of time are due in connection with this response. However, the Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 50-0892.

Also included herewith are: as Exhibit A, a clean copy of the pending claims; as Exhibit B, a marked up copy of the original claims; as Exhibit C, a BLASTP analysis comparing the amino acid sequence of SEQ ID NO: 2 and International Protein Index accession number IPI00083978.2; as Exhibit D, a BLASTN analysis comparing the nucleic acid sequence of SEQ ID NO:1 with GenBank Accession No. XM_084868; as Exhibit E, the GenBank description of Accession No. XM_084868.